(Image: Martin Avery Photography...Mobile 07770661982)
A year of strong growth has seen revenue rise and key commercial milestones reached at a York biotech company.
Aptamer Group reported a 28 per cent increase in revenue to £1.5 million for the 12 months to June 30, 2026, up from £1.2 million the previous year.
The life sciences firm, which develops synthetic binders known as Optimers, also improved its cash position to £4.4 million, supported by a £4.1 million equity raise in April 2026.
Arron Tolley, chief executive officer of Aptamer Group, said: "This has been a year of inflection for Aptamer.
- Aptamer Group of York reports boost in revenue for 2026
- Aptamer Group of York testing for Ebola Bundibugyo strain
- Aptamer Group of York looks to 2026 with confidence
- Aptamer Group of York reports 27% rise in revenues
"We have moved from proving our technology to proving our business model with two royalty-bearing licences now signed, repeat orders from multiple top 20 pharmaceutical companies, and our first entry into the radioligand therapy market.
"Following April's fundraise, we have used the proceeds to build the foundations for the next phase of growth.
"Our AI programme has progressed from a standing start to candidate validation in a matter of months, our manufacturing capacity has been expanded to support partners at commercial scale, and we are now building a therapeutic pipeline spanning RNAi delivery to multiple diseases and organs including fibrosis and kidney, along with radiopharmaceuticals.
"We enter the new financial year with recurring fee-for-service demand, growing licensing income, and multiple development programmes advancing in our own pipeline.
"I would like to thank our partners, shareholders and the whole Aptamer team for their continued support, and I look forward to updating the market as this progress continues to build."
Adjusted EBITDA loss was £2.3 million, in line with the previous year's £2.2 million, while administration expenses rose to £3.2 million from £2.9 million.
The board said the current cash balance provides a financial runway into 2028, excluding any additional licensing income.
Aptamer Group reported repeat business from multiple top 20 pharmaceutical companies and secured royalty-bearing licences, including agreements with Twist Bioscience and Alphazyme.
The company also completed a second development programme with Unilever and launched a targeted radiotherapeutic programme, delivering materials for in vivo animal studies.
Post-period, the sales pipeline grew from £4.8 million to £7 million by September 21, 2026.
The company is moving towards multi-year, multi-target master service agreements with several major pharmaceutical customers.
Aptamer Group is also developing licensable assets in the enzyme and cosmetics sectors.
Cavendish Capital Markets has been appointed as joint corporate broker alongside Turner Pope Investments.
The company has expanded its manufacturing capacity through the deployment of new automation machinery to support future revenue growth.
It also reported strong progress in AI-driven candidate screening and validation.